ABL1 and neoplasm: Because GADD45α is considered a tumour suppressor of BCR-ABL driven leukaemia [27, 35], we measured the expression of GADD45α by immunohistochemistry in the neoplasm tissue extracted from miR-362-5p inhibitor and control mice.